Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9070317 | 0.86 | AOC3 (0.54) | HDAC4HDAC8AOC3ALDH1A1CYP3A4 | |
| SCHEMBL19122369 | 0.86 | AOC3 (0.54) | HDAC4HDAC8AOC3ALDH1A1CYP3A4 | |
| SCHEMBL3096347 | 0.84 | AOC3 (0.56) | AOC3HTR2B | |
| SCHEMBL20852303 | 0.84 | CYP3A4 (0.47) | AOC3ALDH1A1CA1CA2TP53 | |
| SCHEMBL8801783 | 0.84 | SLC6A3 (0.38) | HDAC4HDAC8AOC3CYP3A4 | |
| SCHEMBL3319428 | 0.84 | IDO1 (0.46) | ALDH1A1TP53MAPTHTR2B | |
| SCHEMBL15854161 | 0.84 | AOC3 (0.56) | HDAC4AOC3KDM4EACHE | |
| SCHEMBL9157662 | 0.84 | CYP3A4 (0.47) | AOC3ALDH1A1CA1CA2TP53 | |
| SCHEMBL18912756 | 0.84 | ADRB1 (0.53) | KDM4EALDH1A1CA2CYP3A4TYR | |
| SCHEMBL7606483 | 0.84 | AOC3 (0.56) | AOC3ALDH1A1CA1CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888401-B2 | Ink composition and inkjet ink, and image-forming method and recorded material using the same, and oxetane compound | FUJIFILM CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20080033072-A1 | Ink composition and inkjet ink, and image-forming method and recorded material using the same, and oxetane compound | FUJIFILM CORPORATION (JP) | 2008-02-07 | — | — | US | disclosed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | disclosed |
| EP-0687253-B1 | 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME | BOEHRINGER MANNHEIM GMBH (DE) | 1998-12-16 | — | — | EP | disclosed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033072-A1 | Ink composition and inkjet ink, and image-forming method and recorded material using the same, and oxetane compound | OXER1, IPO11, NOXO1 | HDAC4 2014/4885HDAC8 1767/4885AOC3 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.